Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
manufacturing delay
Pharma
An Alnylam blockbuster-to-be faces a manufacturing delay at FDA
Alnylam must wait a few months longer for a verdict on its potential blockbuster-in-waiting vutrisiran.
Fraiser Kansteiner
Apr 4, 2022 10:55am
Samsung Pharm hit with production suspension
Nov 8, 2021 3:15am
Novartis unsure when FDA might OK its once-rejected inclisiran
Jan 26, 2021 9:25am
FDA inspection backlog could keep growing as pandemic rages
Dec 22, 2020 3:00am
Bluebird tanks with FDA delay of LentiGlobin in sickle cell
Nov 5, 2020 10:58am
Nabriva hit with 2nd FDA complete response letter for Contepo
Jun 22, 2020 10:00am
